Paul Vandecruys

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?

Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?

Journal: Expert review of anti-infective therapy

Published: April 14, 2026

Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses.

Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses.

Journal: Nature communications

Published: June 10, 2025

Accumulation of Trehalose 6-Phosphate in Candidozyma auris results in Decreased Echinocandin Resistance and Tolerance.

Accumulation of Trehalose 6-Phosphate in Candidozyma auris results in Decreased Echinocandin Resistance and Tolerance.

Journal: Nature communications

Published: May 16, 2025

Multi-step pathway engineering in probiotic Saccharomyces boulardii for abscisic acid production in the gut.

Multi-step pathway engineering in probiotic Saccharomyces boulardii for abscisic acid production in the gut.

Journal: Metabolic engineering communications

Published: December 22, 2024

Metabolic Engineering and Process Intensification for Muconic Acid Production Using Saccharomyces cerevisiae.

Metabolic Engineering and Process Intensification for Muconic Acid Production Using Saccharomyces cerevisiae.

Journal: International journal of molecular sciences

Published: July 29, 2024

Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance.

Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance.

Journal: Applied and environmental microbiology

Published: May 16, 2024

Acquired amphotericin B resistance leads to fitness trade-offs that can be mitigated by compensatory evolution in Candida auris.

Acquired amphotericin B resistance leads to fitness trade-offs that can be mitigated by compensatory evolution in Candida auris.

Journal: Nature microbiology

Published: August 28, 2023

New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.

New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.

Journal: Applied microbiology and biotechnology

Published: August 15, 2023

Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC).

Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC).

Journal: Expert review of anti-infective therapy

Published: July 14, 2023

Sources of Antifungal Drugs.

Sources of Antifungal Drugs.

Journal: Journal of fungi (Basel, Switzerland)

Published: December 31, 2022

In Vitro Assessment of Azole and Amphotericin B Susceptibilities of Malassezia spp. Isolated from Healthy and Lesioned Skin.

In Vitro Assessment of Azole and Amphotericin B Susceptibilities of Malassezia spp. Isolated from Healthy and Lesioned Skin.

Journal: Journal of fungi (Basel, Switzerland)

Published: August 11, 2022

The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.

The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.

Journal: Frontiers in microbiology

Published: May 06, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026